Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study. (27th October 2022)

• Record Type: Journal Article
• Authors: En‐nasery ‐ de Heer, Selma; Tromp, Vashti N. M. F.; Westerman, Marjan J.; Konings, Inge; Beckeringh, Jan Jacob; Boons, Christel L. M.; Timmers, Lonneke; Hugtenburg, Jacqueline G.
• Is Part Of: European journal of cancer care. Volume 31:Number 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-10-27
• Subjects: adjuvant endocrine therapy -- breast cancer -- eHealth -- medication adherence -- patient views -- pharmaceutical care; Cancer -- Nursing -- Periodicals; 616.994
• DOI: 10.1111/ecc.13749
• Languages: English
• ISSNs: 0961-5423

Abstract

Abstract: Objective: The use of adjuvant endocrine therapy (AET) after primary treatment of hormone receptor‐positive breast cancer reduces the risk of recurrence and mortality. However, non‐adherence is still common. Limited consideration has been given to how users deal with AET and the role of pharmaceutical care. Therefore, this study aims to obtain insight into the needs and wishes of women using AET regarding pharmaceutical care and eHealth. Methods: This is a qualitative explorative study comprising semi‐structured interviews ( n = 16) and a focus group ( n = 5) among women who use or used AET after primary early‐stage breast cancer (EBC) treatment using a thematic analysis approach. Results: Three themes emerged from the interviews and focus group: (1) experiences with AET use, (2) experiences with provided information and (3) needs and wishes regarding pharmaceutical care. Most women were highly motivated to use AET and indicated to have received useful information on AET. However, many expressed a strong need for more elaborate tailored and timely provided information on AET. They acknowledged the accessibility of pharmacists but reported that currently, pharmacists are hardly involved in AET care. Several women considered eHealth useful to obtain counselling and reliable information. Conclusion: Women need more comprehensive information and follow‐up in primary setting after initial cancer treatments. A more elaborate role for the pharmacy and eHealth/mHealth, especially with regard to counselling on side effects and side effect management, could potentially improve pharmaceutical care.